However, evaluating the potential beneficial effects of PAI-1 inhibitors in the setting of IH is essential to assess whether PAI-1 is potentially a recommended approach as a therapeutic target in OSA-mediated CVD. Here, SERPINE1 is linked to isolated hemihyperplasia.